GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Notes Receivable

Andros Pharmaceuticals Co (ROCO:6917) Notes Receivable : NT$0.00 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co Notes Receivable?

Andros Pharmaceuticals Co's Notes Receivable for the quarter that ended in Jun. 2024 was NT$0.00 Mil.


Andros Pharmaceuticals Co Notes Receivable Historical Data

The historical data trend for Andros Pharmaceuticals Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co Notes Receivable Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - - -

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only - - - - -

Andros Pharmaceuticals Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Andros Pharmaceuticals Co Notes Receivable Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Andros Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co Headlines

No Headlines